World Journal of Pharmaceutical and Life Sciences
WJPLS
www.wjpls.org
SJIF Impact Factor: 7.409

FROM DATA TO DRUGS: THE ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN MODERN MEDICINAL CHEMISTRY

Mahesh Kumar N.[1*], Priya A.[2] and Dr. Shachindra L. Nargund[3]

[1,2]PG Scholar, Department of Pharmaceutical Chemistry, Nargund College of Pharmacy, Bengaluru-560085, India.
[3]Professor & Principal, Department of Pharmaceutical Chemistry, Nargund College of Pharmacy, Bengaluru-560085, India.

***Corresponding Author: Mahesh Kumar N.**
PG Scholar, Department of Pharmaceutical Chemistry, Nargund College of Pharmacy, Bengaluru-560085, India.

Article Received on 24/06/2025 **Article Revised on 14/07/2025** **Article Accepted on 04/08/2025**

ABSTRACT
This review explores how AI and machine learning are transforming medicinal chemistry by enhancing drug discovery processes such as target identification, screening, SAR modelling, and molecular design. It outlines key AI/ML methods, presents real-world case studies, and examines challenges like data quality and ethical concerns. Advances like transfer learning and explainable AI are also discussed, emphasizing the need for collaboration to fully harness AI's potential in drug development.

GRAPHICAL ABSTRACT



KEYWORDS: Drug discovery, Deep learning, Transfer learning, Explainable AI, Structure–activity relationships, De novo design.

1. INTRODUCTION

Drug discovery has traditionally been a lengthy, expensive, and uncertain process, often taking over a decade with an estimated cost exceeding $2.6 billion per approved drug.[1] Despite the progress in high-throughput screening, combinatorial chemistry, and genomics, the pharmaceutical industry continues to face challenges, including low success rates in clinical trials and increasing attrition due to safety or efficacy issues.[2] In this context, artificial intelligence (AI) and machine learning (ML) have emerged as transformative technologies in medicinal chemistry, offering the ability to analyse vast and complex datasets, recognize hidden patterns, and make data-driven predictions that enhance various stages of drug discovery and development.[3] These technologies enable researchers to move beyond traditional trial-and-error methods, making the drug discovery process faster, cheaper, and more precise.

AI refers to the simulation of human cognitive processes by machines, including learning, reasoning, and decision-making. ML, a subfield of AI, focuses on algorithms that learn from data to make predictions or decisions without being explicitly programmed.[4] The

increasing availability of public chemical and biological databases, along with advances in computational infrastructure such as GPUs and cloud computing, has fuelled the application of AI in the pharmaceutical sciences.[5] Deep learning (DL), a subdomain of ML based on artificial neural networks with multiple hidden layers, has demonstrated remarkable success in fields like natural language processing, computer vision, and more recently, drug discovery.[6] These advances have enabled the prediction of molecular properties, bioactivity, toxicity, and drug-likeness with unprecedented accuracy.

2. OVERVIEW OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING

Artificial intelligence encompasses a broad range of computational strategies designed to mimic human intelligence. In medicinal chemistry, AI-driven tools are used to predict drug-target interactions, generate novel molecules, optimize pharmacokinetic properties, and facilitate synthetic planning.[7] The two main branches of AI relevant to this field are symbolic AI and data-driven AI. While symbolic AI involves rule-based systems and logic programming, data-driven AI dominated by ML and DL learns directly from data patterns.[8]

Machine learning is generally classified into supervised, unsupervised, semi-supervised, and reinforcement learning.

Supervised learning relies on labelled datasets where both input (e.g., molecular descriptors) and output (e.g., biological activity) are known. Algorithms such as support vector machines (SVMs), random forests (RFs), k-nearest neighbors (KNN), and gradient boosting machines (GBMs) are commonly applied to structure–activity relationship (SAR) and quantitative structure–activity relationship (QSAR) modelling.[9]

Unsupervised learning is applied when there is no labelled output. It is particularly useful in clustering chemical compounds, visualizing chemical space, and detecting hidden substructures in molecular datasets.[10] Techniques like k-means clustering, hierarchical clustering, and principal component analysis (PCA) fall under this category.

Reinforcement learning (RL) is an advanced ML paradigm where an agent learns to perform tasks by receiving rewards or penalties from the environment. In medicinal chemistry, RL has been used to guide the design of molecules with specific desired properties, such as binding affinity and synthetic accessibility.[11]

Deep learning (DL) extends traditional ML by employing deep neural networks composed of multiple layers. These architectures, including convolutional neural networks (CNNs), recurrent neural networks (RNNs), and graph neural networks (GNNs), can automatically extract meaningful features from complex molecular representations such as SMILES strings, molecular graphs, or 3D structures.[12] A significant component of ML success in medicinal chemistry lies in the proper representation of molecules. Molecular descriptors, fingerprints (e.g., MACCS, ECFP), graph representations, and tokenized sequences (e.g., SMILES) are commonly used to encode molecules into formats suitable for ML algorithms.[13] Model performance is typically assessed using metrics like accuracy, F1 score, ROC-AUC, root mean square error (RMSE), and R-squared. Best practices in ML model development also include cross-validation, external test sets, and hyperparameter tuning to prevent overfitting and improve generalizability.[14] With access to high-quality datasets such as ChEMBL, PubChem, BindingDB, and TOX21, ML models can now be trained on millions of compounds and bioactivity annotations, creating opportunities to transform various aspects of medicinal chemistry.[15]

3. APPLICATIONS IN MEDICINAL CHEMISTRY

AI and ML have demonstrated wide-ranging applications across the drug development pipeline, from initial hit identification to clinical trial design. These technologies are not intended to replace human intuition, but rather to enhance it through computational insights derived from large-scale data.

3.1 Virtual Screening and Hit Identification

Virtual screening (VS) is a computational method used to identify biologically active compounds from large chemical libraries. ML-based VS models, including random forests, SVMs, and deep neural networks, have demonstrated superior performance over traditional docking by learning nonlinear relationships between molecular features and activity.[16] A well-known example is Atomwise's AtomNet, which uses deep convolutional neural networks trained on 3D structural data to predict protein-ligand binding affinity. AtomNet has been successfully used to identify novel inhibitors against diseases such as Ebola, leukaemia, and antibiotic-resistant bacteria.[17]

3.2 De Novo Drug Design

De novo drug design aims to generate novel molecules with optimized biological and physicochemical properties. Generative models such as variational autoencoders (VAEs), recurrent neural networks (RNNs), and generative adversarial networks (GANs) are increasingly used for this task. These models learn from large datasets of existing molecules and generate new chemical structures that follow medicinal chemistry principles while satisfying constraints such as target selectivity or synthetic accessibility.[18] Reinforcement learning has also been applied to refine the generation process toward specific objectives such as increased potency or decreased toxicity.[19]

3.3 Target Prediction and Validation

Accurate prediction of drug-target interactions (DTIs) is vital for understanding mechanisms of action, side effects, and off-target effects. ML models trained on chemogenomic data can predict novel DTIs by integrating molecular features of drugs with protein features such as amino acid sequences or structural domains.[20] Graph convolutional networks (GCNs) and matrix factorization techniques have been widely used in this domain, providing a scalable approach for polypharmacology analysis.[21]

3.4 QSAR and SAR Modelling

Quantitative structure–activity relationship (QSAR) and structure–activity relationship (SAR) models are central to medicinal chemistry. ML enhances QSAR modelling by enabling the use of non-linear and high-dimensional feature spaces. Algorithms such as gradient boosting, support vector regression (SVR), and deep neural networks allow accurate predictions of activity, potency, and selectivity.[22] Recent efforts have also introduced interpretable models using SHAP (SHapley Additive exPlanations) and LIME (Local Interpretable Model-agnostic Explanations) to uncover key molecular features driving activity.[23]

3.5 ADMET Prediction

One of the major causes of failure in drug development is poor pharmacokinetic or safety profiles. AI models trained on high-quality experimental datasets can predict ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties with high accuracy. For example, models developed using TOX21 data have been employed to predict liver toxicity, blood-brain barrier permeability, and hERG inhibition. Deep learning models such as graph attention networks and transformers can incorporate both chemical and biological context to improve prediction accuracy.[24]

3.6 Drug Repurposing

AI and ML have been employed to identify new therapeutic indications for existing drugs—a strategy known as drug repurposing. This approach gained particular attention during the COVID-19 pandemic when ML models predicted baricitinib as a promising treatment for SARS-CoV-2 infection.[25] NLP algorithms using biomedical literature, patient data, and clinical trial results help uncover hidden associations between drugs and diseases, accelerating repurposing opportunities.

3.7 Reaction Prediction and Retrosynthesis

Retrosynthetic analysis is essential for planning synthetic routes to drug candidates. Transformer-based models, such as IBM RXN and Molecular Transformer, have been trained on millions of reactions to predict both reaction outcomes and synthesis pathways. These models outperform rule-based systems in predicting regioselectivity, yield, and reaction feasibility, making them valuable tools for medicinal chemists.[26]

4. COMPUTATIONAL TOOLS AND PLATFORMS

The implementation of AI and ML in medicinal chemistry relies heavily on robust computational tools and platforms. These resources enable chemists and data scientists to build predictive models, manipulate chemical structures, and simulate complex biochemical interactions. This section categorizes these resources into open-source libraries, cheminformatics tools, and commercial AI-driven platforms.

4.1 Open-Source Libraries: Open-source machine learning libraries have played a foundational role in enabling the application of AI techniques in medicinal chemistry. Among the most widely used are.

- **Scikit-learn:** A Python-based library offering a rich suite of supervised and unsupervised learning algorithms. Scikit-learn is especially useful for basic classification, regression, clustering, and dimensionality reduction tasks. Its user-friendly API and compatibility with other Python libraries like NumPy and Pandas make it ideal for rapid prototyping in cheminformatics.
- **TensorFlow:** Developed by Google Brain, TensorFlow provides a flexible platform for designing and deploying large-scale deep learning models. It supports both CPU and GPU computation, which is particularly important when training complex models on large molecular datasets.
- **PyTorch:** Created by Facebook's AI Research lab, PyTorch is widely appreciated for its dynamic computation graph and ease of debugging. It is increasingly favoured for research in deep learning applications, including drug–target interaction modelling and graph-based neural networks used in molecular property prediction.[27] These libraries serve as the backbone for algorithm development, allowing researchers to customize model architectures for specific medicinal chemistry tasks.

4.2 Cheminformatics Tools: To translate molecular structures into machine-readable formats, cheminformatics tools are essential. These tools bridge the gap between raw molecular data and machine learning models.

- **RDKit:** A widely-used open-source toolkit that offers capabilities such as molecule visualization, descriptor calculation, structure standardization, and substructure searching. RDKit is often integrated into ML workflows for feature extraction and compound filtering.
- **Open Babel:** A chemical toolbox that facilitates the interconversion of chemical file formats (e.g., SMILES, SDF, MOL). It supports various structure manipulation and optimization functions that are critical for pre-processing in virtual screening.
- **DeepChem:** A deep learning framework specifically tailored for drug discovery and cheminformatics. Built on TensorFlow, DeepChem provides ready-to-use models for tasks like molecular property

prediction, protein–ligand binding affinity estimation, and toxicity classification.[28] These tools allow the encoding of chemical knowledge into numerical features, making them indispensable for data-driven research in medicinal chemistry.

4.3 Commercial Platforms: In addition to open-source resources, several biotechnology and AI-focused companies have developed proprietary platforms that integrate ML into various stages of drug development:

- **Benevolent AI:** Focuses on using knowledge graphs and deep learning to uncover novel drug–disease relationships. Its platform leverages biomedical literature, genomic data, and clinical trial data to generate new hypotheses for drug repurposing and target discovery.[29]

These platforms highlight the translational impact of AI in the pharmaceutical industry, offering not only predictive models but also integrated solutions that streamline the path from molecule design to clinical validation.

5. CASE STUDIES

5.1 Atomwise and AtomNet

Atomwise has been a pioneering force in the application of deep learning for drug discovery. Its platform, AtomNet, utilizes convolutional neural networks to predict the bioactivity of small molecules based on their three-dimensional structural information. One of the hallmark successes of AtomNet includes the identification of potent inhibitors for Ebola virus proteins, where the system screened millions of compounds and produced high-probability candidates within days.[30] These compounds later demonstrated significant activity in in-vitro studies, showcasing the speed and predictive power of AI-driven approaches in crisis situations.

5.2 Exscientia

Exscientia is a UK-based pharmaceutical AI company known for integrating AI with medicinal chemistry design principles. In 2020, Exscientia announced the development of a selective serotonin 5-HT1A receptor agonist, which was designed, optimized, and advanced to human clinical trials in less than 12 months, a significant reduction from the industry average of 4–5 years.[31] This achievement demonstrates how AI platforms can optimize lead identification, synthetic accessibility, and pharmacological profiling simultaneously.

5.3 IBM Watson for Drug Discovery

IBM Watson applies natural language processing (NLP) and graph analytics to mine scientific literature, clinical trial databases, and biomedical datasets. In a repurposing study, Watson identified previously overlooked molecules with potential applications in oncology and infectious diseases.[32] One example includes Watson's role in identifying potential repurposed therapies for glioblastoma, showcasing how AI can accelerate hypothesis generation by integrating diverse data sources.

6. CHALLENGES IN AI IMPLEMENTATION

6.1 Data Quality and Quantity

AI models, especially supervised learning algorithms, demand large volumes of clean, annotated data. In the pharmaceutical domain, datasets are often imbalanced, with few active compounds compared to inactive ones. Moreover, experimental errors and inconsistent bioassay formats can introduce noise, negatively impacting model performance.[33] Additionally, the lack of negative data (e.g., failed experiments) limits AI models from learning complete decision boundaries.

6.2 Interpretability

AI systems particularly deep neural networks (DNNs) are often criticized for their lack of transparency. These models function as black boxes, making it difficult for chemists and regulators to understand why a model made a particular prediction.[34] This limitation poses serious challenges when AI-generated predictions are used in clinical or regulatory decision-making, where explainability is essential.

6.3 Integration with Traditional Chemistry

While AI models offer impressive capabilities, they must be used to complement the domain knowledge of medicinal chemists rather than replace it. Seamless integration of AI platforms into drug discovery workflows, including synthetic route planning, SAR interpretation, and ADMET optimization, remains underdeveloped.[35] Moreover, many chemists lack the computational expertise required to interact effectively with ML models, leading to underutilization.

6.4 Ethical and Regulatory Considerations

AI-driven research raises concerns about data privacy, patient consent, and algorithmic bias. For example, training data that underrepresents certain populations can lead to models that are biased or unreliable for minority groups.[36] Moreover, regulatory frameworks (e.g., FDA, EMA) currently lack standardized guidelines for AI validation, making it challenging to get AI-developed drug candidates through regulatory approval pipelines.

7. RECENT ADVANCES

7.1 Transfer Learning

Transfer learning is an emerging solution to the problem of limited data. In this approach, a model trained on a large, general-purpose dataset is fine-tuned on a smaller, domain-specific dataset. This methodology has shown substantial improvements in QSAR modelling, protein–ligand interaction predictions, and bioactivity forecasting.[37] It enables the reuse of computational knowledge across different chemical or biological domains, significantly improving model accuracy.

7.2 Federated Learning

Federated learning allows multiple organizations (e.g., pharmaceutical companies, hospitals) to collaboratively train a model without sharing sensitive data. Each entity retains its own data locally and only shares the model updates, preserving privacy while enabling learning across larger datasets.[38] This paradigm is gaining traction in multi-institutional drug repurposing studies and pharmacovigilance applications.

7.3 Explainable AI (XAI)

Explainable AI (XAI) techniques are being developed to enhance the interpretability of AI predictions. Tools such as SHAP (SHapley Additive exPlanations), LIME (Local Interpretable Model-Agnostic Explanations), and attention visualization in neural networks allow users to identify which features most influenced a model's decision. XAI is crucial for building trust among end-users (e.g., medicinal chemists) and meeting regulatory.

8. FUTURE PERSPECTIVES

The integration of AI and ML with quantum computing, multi-omics data, and synthetic biology will reshape the landscape of drug discovery. For instance, quantum ML algorithms can enable the accurate simulation of complex molecular interactions beyond the capabilities of classical computing.[39] Likewise, multi-omics integration (genomics, proteomics, metabolomics) using AI will facilitate the discovery of personalized medicines and biomarkers. In the near future, AI tools will evolve from being just predictive engines to interactive design platforms, assisting chemists in real-time during molecular design. Interdisciplinary collaboration between data scientists, regulatory agencies, and bench chemists is key to overcoming current limitations and democratizing AI access across small and large pharma alike.[40]

9. CONCLUSION

AI and ML technologies have become indispensable in modern medicinal chemistry, enabling faster, more efficient, and more intelligent drug discovery pipelines. From virtual screening and lead optimization to toxicity prediction and compound design, AI enhances nearly every stage of drug development. This review aims to provide an in-depth analysis of the role of AI and ML in medicinal chemistry, beginning with a conceptual overview and then delving into their specific applications in drug discovery, design, screening, and optimization. Though challenges such as data quality, interpretability, and ethical concerns persist, recent innovations like transfer learning, federated models, and explainable AI offer promising solutions. The future of drug discovery lies at the convergence of chemical expertise, computational innovation, and ethical oversight, with AI poised to serve as a powerful catalyst for pharmaceutical advancement.

10. ACKNOWLEDGMENT

The authors express gratitude for the management of Nargund College of Pharmacy and the Department of Pharmaceutical Chemistry for their valuable support and encouragement.

REFERENCES

1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. *J Health Econ*, 2016; 47: 20–33.
2. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov*, 2010; 9(3): 203–14.
3. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*, 2019; 18(6): 463–77.
4. Jordan MI, Mitchell TM. Machine learning: Trends, perspectives, and prospects. *Science*, 2015; 349(6245): 255–60.
5. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. *Drug Discov Today*, 2018; 23(6): 1241–50.
6. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature*, 2015; 521(7553): 436–44.
7. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol*, 2019; 37(9): 1038–40.
8. Chen H, Zhang Z, Wang Y. The use of machine learning algorithms in drug discovery. *Sci Prog*, 2021; 104(3): 00368504211032986.
9. Lo Y-C, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. *Drug Discov Today*, 2018; 23(8): 1538–46.
10. Goh GB, Hodas NO, Vishnu A. Deep learning for computational chemistry. *J Comput Chem*, 2017; 38(16): 1291–307.
11. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. *Sci Adv*, 2018; 4(7): eaap7885.
12. Altae-Tran H, Ramsundar B, Pappu AS, Pande V. Low data drug discovery with one-shot learning. *ACS Cent Sci*, 2017; 3(4): 283–93.
13. Rogers D, Hahn M. Extended-connectivity fingerprints. *J Chem Inf Model*, 2010; 50(5): 742–54.
14. Sheridan RP. Time-split cross-validation as a method for estimating the goodness of prospective prediction. *J Chem Inf Model*. 2013; 53(4): 783–90.
15. Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, et al. The ChEMBL database in 2017. *Nucleic Acids Res*, 2017; 45(D1): D945–54.

16. Lavecchia A. Deep learning in drug discovery: opportunities, challenges and future prospects. *Drug Discov Today*, 2019; 24(10): 2017–32.
17. Wallach I, Dzamba M, Heifets A. AtomNet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery. *arXiv preprint* arXiv: 1510.02855. 2015.
18. Gómez-Bombarelli R, Wei JN, Duvenaud D, Hernández-Lobato JM, Sánchez-Lengeling B, Sheberla D, et al. Automatic chemical design using a data-driven continuous representation of molecules. *ACS Cent Sci*, 2018; 4(2): 268–76.
19. Olivecrona M, Blaschke T, Engkvist O, Chen H. Molecular de-novo design through deep reinforcement learning. *J Cheminform*, 2017; 9(1): 48.
20. Ezzat A, Wu M, Li X-L, Kwoh C-K. Drug–target interaction prediction with graph regularized matrix factorization. *IEEE/ACM Trans Comput Biol Bioinform*, 2017; 14(3): 646–56.
21. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. *Bioinformatics*, 2018; 34(13): i457–66.
22. Lenselink EB, Ten Dijke N, Bongers BJ, Papadatos G, van Vlijmen HWT, Kowalczyk W, et al. Beyond the hype: deep neural networks outperform established methods using a ChEMBL bioactivity benchmark set. *J Cheminform*, 2017; 9(1): 45.
23. Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. *Adv Neural Inf Process Syst.* 2017; 30.
24. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using deep learning. *Front Environ Sci*, 2016; 3: 80.
25. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. *Lancet*, 2020; 395(10223): e30–1.
26. Schwaller P, Laino T, Gaudin T, Bolgar P, Hunter CA, Bekas C, et al. Molecular transformer: A model for uncertainty-calibrated chemical reaction prediction. *ACS Cent Sci*, 2019; 5(9): 1572–83.
27. Pedregosa F, et al. Scikit-learn: Machine learning in Python. J Mach Learn Res, 2011; 12: 2825–2830.
28. Landrum G. RDKit: Open-source cheminformatics. [Internet]. [cited 2025 Jul 30]. Available from: https: //www.rdkit.org
29. Stokes JM, et al. A deep learning approach to antibiotic discovery. Cell, 2020; 180(4): 688–702.e13.
30. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. *Cell*, 2020; 180(4): 688–702.e13.
31. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. *Drug Discov Today*. 2004; 9(10): 430–1.
32. Ferrucci D. Introduction to "This is Watson". *IBM J Res Dev*, 2012; 56(3.4): 1–15.
33. Kearnes S, Goldman B, Pande V. Modeling industrial ADMET data with multitask networks. *arXiv preprint* arXiv: 1606.08793. 2016.
34. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, et al. From local explanations to global understanding with explainable AI for trees. *Nat Mach Intell*, 2020; 2(1): 252–9.
35. Schneider G. Automating drug discovery. *Nat Rev Drug Discov*, 2018; 17(2): 97–113.
36. Char DS, Shah NH, Magnus D. Implementing machine learning in health care—addressing ethical challenges. *N Engl J Med*, 2018; 378(11): 981–3.
37. Ragoza M, Hochuli J, Idrobo E, Sunseri J, Koes DR. Protein–ligand scoring with convolutional neural networks. *J Chem Inf Model*, 2017; 57(4): 942–57.
38. Sheller MJ, Reina GA, Edwards B, Martin J, Bakas S. Multi-institutional deep learning modeling without sharing patient data: a feasibility study on brain tumor segmentation. *Brainlesion*, 2019; 11383: 92–104.
39. Biamonte J, Wittek P, Pancotti N, Rebentrost P, Wiebe N, Lloyd S. Quantum machine learning. *Nature*, 2017; 549(7671): 195–202.
40. Choudhury A, Gupta R, Ghosh SK, Talukdar P. A robust, explainable AI framework for predicting adverse drug reactions. *Bioinformatics*, 2021; 37(Suppl_1): 126–35.